Contract Option Exercises — April 01, 2026

Over $2B in obligations to space vehicle/instrument providers like RTX and Lockheed through 2026-2029, with $760M+ already outlayed.

$1B+ in engineering, logistics, and remediation contracts to HII, TRAX, and Sevenson, with options adding $600M+ potential.

HHS $256M botulism antitoxin deal for Emergent and DOI $117M facility build for Hensel Phelps provide multi-year fixed-price revenue.

Long performance periods (5-18 years to 2032) with low outlays (e.g., 14-25% disbursed on RTX, Lockheed) heighten delivery and cost control risks.

Funding tied to annual appropriations for NASA/DoD contracts; foreign ownership in Emergent Canada may draw scrutiny.

$600M+ in unobligated options across contracts (e.g., HII $509M, Sevenson $19M) for engineering and remediation services.

Follow-on potential from reissued/legacy NASA contracts (e.g., TRAX, RTX) and DoD remediation.

67% of value ($2.06B) in NASA awards for instruments, vehicles, and R&D through 2029, favoring primes with low-competition wins.

75% of contracts use cost-plus structures, reducing pricing risk but tying upside to performance fees.

{"entity"=>"RTX (Raytheon)", "reason"=>"$1.22B NASA obligation with $939M remaining and 2029 horizon.", "trigger"=>"Option exercise unlocking $32M; outlay acceleration"}

{"entity"=>"Lockheed Martin", "reason"=>"$301M MAVEN extension to 2026 with low 14% outlay.", "trigger"=>"Increased disbursements signaling Phase B progress"}

{"entity"=>"HII Mission Technologies", "reason"=>"$446M obligation with $509M options nearing 2025 end.", "trigger"=>"Follow-on GSA task orders"}